These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21645456)

  • 1. [Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer].
    Fang Q; Zhang L; Wang S; Ou W
    Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):518-22. PubMed ID: 21645456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
    Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
    Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.
    Sun L; Zhang Q; Luan H; Zhan Z; Wang C; Sun B
    J Exp Clin Cancer Res; 2011 Mar; 30(1):30. PubMed ID: 21414214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
    Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
    Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
    Han C; Zou H; Ma J; Zhou Y; Zhao J
    Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of epidermal growth factor receptor mutations between primary tumors and lymph nodes in non-small cell lung cancer: a review and meta-analysis of published data.
    Wang F; Fang P; Hou DY; Leng ZJ; Cao LJ
    Asian Pac J Cancer Prev; 2014; 15(11):4493-7. PubMed ID: 24969875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.
    Park S; Holmes-Tisch AJ; Cho EY; Shim YM; Kim J; Kim HS; Lee J; Park YH; Ahn JS; Park K; Jänne PA; Ahn MJ
    J Thorac Oncol; 2009 Jul; 4(7):809-15. PubMed ID: 19487967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis.
    Lee CC; Soon YY; Tan CL; Koh WY; Leong CN; Tey JCS; Tham IWK
    PLoS One; 2019; 14(6):e0218414. PubMed ID: 31216329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer.
    Wei B; Yang K; Zhao J; Chang Y; Ma Z; Dong B; Guo Y; Ma J
    J Exp Clin Cancer Res; 2014 Jan; 33(1):5. PubMed ID: 24398248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.
    Badalian G; Barbai T; Rásó E; Derecskei K; Szendrôi M; Tímár J
    Pathol Oncol Res; 2007; 13(2):99-104. PubMed ID: 17607370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
    Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
    J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
    Wang S; Wang Z
    Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy.
    Lv P; Yang S; Liu W; Qin H; Tang X; Wu F; Liu Z; Gao H; Liu X
    Thorac Cancer; 2020 Jan; 11(1):29-40. PubMed ID: 31691525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.
    Shimizu K; Yukawa T; Hirami Y; Okita R; Saisho S; Maeda A; Yasuda K; Nakata M
    Target Oncol; 2013 Dec; 8(4):237-42. PubMed ID: 23212424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.